Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sertraline in Low-Risk MDS
NCT02452983Phase 1Terminated
- Start
- May 2015
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sertraline in myelodysplastic syndrome (MDS). Primary endpoint: Hematological Improvement - minor at 16 weeks. Started May 2015; status: terminated.
02
Drugs
sertraline
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02452983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02452983.